Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus PROMAPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus PROMAPAR.
MELLARIL vs PROMAPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
PROMAPAR is a brand name for tramadol, a centrally acting analgesic that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, modulating pain perception.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
5 mg orally twice daily, titrated up to maximum 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-15 hours in moderate-to-severe renal impairment.
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal (70-80% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for approximately 20%.
Category C
Category C
Antipsychotic
Antipsychotic